Helena Yu

38PUBLICATIONS
424CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyAnalytical spectrometry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Jul 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Jun 17, 2026
Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

|May 14, 2026
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung Cancer.

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Dec 30, 2025
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib.

Daniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema

Pageof 7

Frequent Collaborators

11 joint publications

Charles M Rudin

7 joint publications

Zofia Piotrowska

6 joint publications

Marc Ladanyi

4 joint publications

Pasi A Jänne